🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region

Recruitingn/aAges any - anyAllAstraZeneca
NCT07065344 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231. Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of NHL, accounting for 30%-40% of cases2. DLBCL is an aggressive malignancy with heterogeneous biology and behavior. Disease risk stratification and treatment planning involve various patient and clinical characteristics (e.g., age, stage, and tumor bulk), prognostic indices (e.g., International Prognostic Index (IPI) score), and gene expression profiling. Patients typically present with nodal or extranodal disease, usually exhibiting rapid tumor growth and symptoms that are highly dependent upon the tumor localization. The diagnosis and subtyping of DLBCL have significantly advanced, from morphological assessment of tissue slide to numerous ancillary tests, including immunop

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Male or female patients aged 18 years or older at diagnosis. 2. Patients who have confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) according to the investigator's decision and/or histopathological diagnosis. 3. For Cohort 1: DLBCL patients who are eligible to start treatment\* according to the investigator's decision. 4. For Cohort 2: patients who are diagnosed with DLBCL and have failed at least one prior line of therapy. 5. Patients willing to sign the written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation. Exclusion Criteria: 1. Patients who are not eligible for treatment for any reason, according to the investigator's judgment and decision 2. Patients with concurrent active malignancies other than DLBCL. 3. Patients who are actively participating in any other clinical trial.
💊

What it tests

  • Not listed
📍

Where

21 sites
Research Site
Al Mansurah, Egypt
Research Site
Alexandria, Egypt
Research Site
Cairo, Egypt
Research Site
Sohag, Egypt
Research Site
Tanta, Egypt
Research Site
Baghdad, Iraq
Research Site
Amman, Jordan
Research Site
Kuwait City, Kuwait

…and 13 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy